Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma

Dossett, Lesly A.; Ben-Shabat, Ilan; Bagge, Roger Olofsson; Zager, Jonathan S.

doi:10.1245/s10434-016-5150-2

Cited by 53 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OR rates of 70%‐90% and CR rates up to 60%‐70% are typically achieved with ILP for melanoma ITM . ILI performed for melanoma is associated with OR rates of 60%‐80% and CR rates of 30%‐40% . Despite generally lower reported response rates, ILI may be able to achieve similar local progression‐free survival rates as ILP .…”

Section: Discussionmentioning

confidence: 96%

“…Although novel systemic therapies for advanced melanoma have demonstrated significant survival benefits, there may remain an important role for ILP/ILI in locoregional disease control . OR rates of 70%‐90% and CR rates up to 60%‐70% are typically achieved with ILP for melanoma ITM . ILI performed for melanoma is associated with OR rates of 60%‐80% and CR rates of 30%‐40% .…”

Section: Discussionmentioning

confidence: 99%

“…ILI performed for melanoma is associated with OR rates of 60%‐80% and CR rates of 30%‐40% . Despite generally lower reported response rates, ILI may be able to achieve similar local progression‐free survival rates as ILP . In contrast, immune checkpoint and BRAF kinase inhibitors have demonstrated lower objective response rates in phase 3 randomized trials for unresectable melanoma.…”

Section: Discussionmentioning

confidence: 99%

“…ILP and ILI for melanoma ITM have demonstrated efficacy in locoregional disease control. The overall response (OR) rates achieved with ILP are as high as 70%‐90% and complete response (CR) rates up to 60%‐70% . Both methods of regional therapy were subsequently used for patients with locally advanced STS with similar OR rates, but typically lower CR rates ranging from 18%‐30% …”

Section: Introductionmentioning

confidence: 99%

“…The overall response (OR) rates achieved with ILP are as high as 70%-90% and complete response (CR) rates up to 60%-70%. [7][8][9][10][11] Both methods of regional therapy were subsequently used for patients with locally advanced STS with similar OR rates, but typically lower CR rates ranging from 18%-30%. [12][13][14][15][16][17][18] Over the past decade, the treatment options for advanced melanoma have evolved.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies

Song

Bruce

Fraker

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives Isolated limb perfusion (ILP) and infusion (ILI) are treatment modalities for unresectable melanoma in‐transit metastases and extremity soft tissue sarcomas (STS). We sought to characterize the national trend in their utilization in the context of novel melanoma therapies introduced in 2011. Methods Using the National Inpatient Sample (2005‐2014), patients with a primary diagnosis of limb melanoma or STS who underwent ILP/ILI were identified by diagnosis and procedure codes. Annual percent change (APC) in ILP/ILI procedures was determined. Results From 2005 through 2014, 670 and 130 ILP/ILI procedures were performed for melanoma and STS, respectively. Mean age was 64 (SD 15) years for melanoma and 59 (SD 18) years for STS. Over time, procedures for melanoma decreased with an APC of ‐17 (P = .019). Comparing 2005‐2010 and 2011‐2014, the mean number of procedures for melanoma decreased from 91 to 32 per year (P = .007). In contrast, there was no change for STS (APC 6.5, P = .39; mean 11 and 16 per year in 2005‐2010 and 2011‐2014, respectively, P = .46). Conclusions ILI/ILP utilization has decreased for melanoma, but not for STS. Whether trends for ILP and ILI differed could not be determined. ILP/ILI remains an important option to consider for regional disease control.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies

Song

Bruce

Fraker

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Malignant Melanoma

Ko,

Swetter,

Zager

et al. 2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Melanoma comprises a wide variety of malignant cell types arising from the skin, the mucous membranes, and the pigmented cells of the eye. While these tumors are all classified as melanoma and share a common molecular biology of pigmentation and biological resemblance to cells of neural crest origin, important distinctions in other molecular characteristics and patterns of exposure to ultraviolet light as a carcinogen determine their clinical natural history, including the response to therapeutic interventions. While the majority of melanomas are diagnosed at an early stage and curable with minimal surgery, melanoma has the potential for early and widespread dissemination via lymphatic and hematogenous routes. Surgery remains the mainstay of therapy for primary, regional, and many cases of single‐ or oligo‐metastatic disease, but systemic therapies have dramatically improved the prognosis for metastatic melanoma, particularly immunotherapies that enhance existing cellular immunity. The rapid discovery of new molecular targets, immunotherapy combinations (including the use of radiotherapy), and understanding of the mechanisms of therapeutic resistance are likely to lead to even greater improvements in the prognosis for patients with melanoma in the near future.

show abstract

Malignant Melanoma

Carr

Swetter

et al. 2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Melanoma comprises a wide variety of malignant cell types arising from the skin, the mucous membranes, and the pigmented cells of the eye. While these tumors are all classified as melanoma and share a common molecular biology of pigmentation and biological resemblance to cells of neural crest origin, important distinctions in other molecular characteristics and patterns of exposure to ultraviolet light as a carcinogen determine their clinical natural history, including the response to therapeutic interventions. While the majority of melanomas are diagnosed at an early stage and curable with minimal surgery, melanoma has the potential for early and widespread dissemination via lymphatic and hematogenous routes. Surgery remains the mainstay of therapy for primary, regional, and many cases of single‐ or oligo‐metastatic disease, but systemic therapies have dramatically improved the prognosis for metastatic melanoma, particularly immunotherapies that enhance existing cellular immunity. The rapid discovery of new molecular targets, immunotherapy combinations, and understanding of the mechanisms of therapeutic resistance is likely to lead to even greater improvements in the prognosis for patients with melanoma in the near future.

show abstract

Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma

Abstract: ILP offers an improved ORR, but this does not translate into improved local PFS or OS. Both procedures are well tolerated with minimal regional toxicity.

Cited by 53 publications

References 25 publications

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies

Malignant Melanoma

Malignant Melanoma

Contact Info

Product

Resources

About